title: Endoluminal gastroplication: what are the predictors of outcome?
abstract: BACKGROUND
  Endoluminal gastroplication (EndoCinch) has emerged as an endoscopic anti-reflux therapy, but predictive factors for symptom relief have not been established. The aim of this study was to evaluate the major determinants to predict outcome in patients treated with EndoCinch.
  
  
  METHODS
  A total of 53 consecutive patients, treated with EndoCinch at a single center were included in this prospective study. Inclusion criteria were symptoms of chronic heartburn, dependency on proton-pump inhibitors, documented pathological esophageal acid exposure, and a hiatal hernia smaller than 3 cm in length. All patients underwent endoscopy, 24-h pH monitoring, esophageal manometry, barium esophagram, and a detailed questionnaire regarding their symptoms before treatment. Patients were stratified into a responder and a non-responder group using a questionnaire at 3-month follow-up. A multivariate analysis was performed.
  
  
  RESULTS
  The success rate was 64% (34/53 patients). Three variables weresignificantly predictive for successful endoscopic anti-reflux treatment at the multivariate level: presence of typical symptoms (P=0.01), complete symptom relief with acid suppressive therapy (P=0.01), and normal lower esophageal sphincter pressure (P = 0.04). Not predictive of outcome were age, body mass index, esophagitis, other manometric findings, hiatal hernia size, or pathological level of pH <4/24 h. Barium esophagram did not add any additional predictive information.
  
  
  CONCLUSIONS
  Since no single factor can predict outcome after EndoCinch, a careful patient selection is mandatory to maximize the success rate. The ideal candidate for EndoCinch is a gastroesophageal (GERD) patient with a normal lower esophageal sphincter pressure, whose typical symptoms completely resolved with acid suppressive therapy.
authors.affiliation: Depts of Internal Medicine II and Radiology, University of Leipzig, Leipzig, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Schiefke
authors.forename: H
authors.initials: H
authors.lastname: Soeder
authors.forename: A
authors.initials: A
authors.lastname: Zabel-Langhennig
authors.forename: N
authors.initials: N
authors.lastname: Teich
authors.forename: S
authors.initials: S
authors.lastname: Neumann
authors.forename: G
authors.initials: G
authors.lastname: Borte
authors.forename: J
authors.initials: J
authors.lastname: Mössner
authors.forename: K
authors.initials: K
authors.lastname: Caca
mesh_terms: D000328:Adult; D000368:Aged; D004947:Esophagus / Q000000981:diagnostic imaging / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D018662:Fundoplication; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D011859:Radiography; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors